½ÃÀ庸°í¼­
»óǰÄÚµå
1741302

½ºÇÁ¶óÀ̼¿ ½ÃÀå, ¿ëµµº°, ¿¬·ÉÃþº°, À¯Åë ä³Îº°, Áö¿ªº°

Sprycel Market, By Application, By Age Group, By Distribution Channel:, By Region

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½ºÇÁ¶óÀ̼¿ ½ÃÀåÀº 2025³â¿¡ 23¾ï 4,000¸¸ ´Þ·¯, 2032³â¿¡´Â 28¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2032³â¿¡ °ÉÃÄ CAGR 2.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 23¾ï 4,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 2.80% 2032³â °¡Ä¡ ¿¹Ãø 28¾ï 4,000¸¸ ´Þ·¯

½ºÇÁ¶óÀ̼¿Àº ´Ù»çƼ´ÕÀÇ »óǰ¸íÀ¸·Î, ¾ÏÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â ¾àÁ¦ÀÔ´Ï´Ù. Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦(TKI)·Î ¾Ë·ÁÁø ¾à¹° Ŭ·¡½ºº°·Î ¼ÓÇÕ´Ï´Ù. ´Ù»çƼ´ÕÀº ¾Ï¼¼Æ÷ÀÇ Áõ½Ä°ú ÀüÀÌ¿¡ °ü¿©ÇÏ´Â È¿¼ÒÀΠƯÁ¤ Ƽ·Î½Å Ű³ª¾ÆÁ¦ÀÇ È°¼ºÀ» ÀúÇØÇÔÀ¸·Î½á ÀÛ¿ëÇÕ´Ï´Ù. ½ºÇÁ¶óÀ̼¿Àº ÁַΠƯÁ¤ À¯ÇüÀÇ ¹éÇ÷º´, ƯÈ÷ Çʶóµ¨ÇÇ¾Æ ¿°»öüÀÇ Á¸À縦 Ư¡À¸·Î ÇÏ´Â ±Þ¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´(ALL)(Ph ALL) ¹× ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML)ÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â Ç¥Àû ¾à¹°ÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿ÀÇ ÀϹÝÀûÀÎ ºÎÀÛ¿ëÀ¸·Î´Â ÇÇ·Î, µÎÅë, ¸Þ½º²¨¿ò, ¼³»ç, ü¾× Àú·ù µîÀÌ ÀÖ½À´Ï´Ù. ȯÀÚ¿¡ µû¶ó Ç÷±¸ ¼ö °¨¼Ò, °£Àå¾Ö, ÃâÇ÷ µî º¸´Ù ½É°¢ÇÑ ºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ½À´Ï´Ù. ºÎÀÛ¿ëÀ» °ü¸®ÇÏ°í ´ëóÇϱâ À§Çؼ­´Â °Ç°­ °ü¸® Á¦°ø¾÷üÀÇ ¸é¹ÐÇÑ ¸ð´ÏÅ͸µÀÌ Áß¿äÇÕ´Ï´Ù. CML·Î Áø´ÜµÈ 12°³¿ù ÀÌ»óÀÇ ¼ºÀΰú ¼Ò¾Æ ¸ðµÎ¿¡°Ô Åõ¿©µË´Ï´Ù. ¶ÇÇÑ, Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ¶Ç´Â Ph ALL·Î ¾Ë·ÁÁø ±Þ¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´ÀÇ Æ¯Á¤ ¾ÆÇüÀ» ¾Î°í ÀÖ´Â °°Àº ¿¬·ÉÃþÀÇ ¼ºÀÎ ¹× ¼Ò¾Æ¿¡°Ôµµ ó¹æµË´Ï´Ù. ¹éÇ÷º´Àº °ñ¼ö¿¡¼­ ¹ß»ýÇÏ´Â ¹Ì¼º¼÷ ¹éÇ÷±¸°¡ °ü¿©ÇÏ´Â ¾Ç¼º Á¾¾çÀÔ´Ï´Ù. Á¤»óÀûÀÎ °úÁ¤¿¡¼­ ÀÌ·¯ÇÑ ¹éÇ÷±¸°¡ ¼º¼÷ÇÏ¸é °¨¿°°ú ½Î¿ì°í ½ÅüÀÇ ¸é¿ª ü°è¸¦ À¯ÁöÇϱâ À§ÇØ Ç÷·ù·Î µé¾î°©´Ï´Ù.

½ÃÀå ¿ªÇÐ :

Ç¥Àû ÀûÀÀÁõ Áõ°¡, È¿´É ¹× ¾ÈÀü¼ºÇÁ·ÎÆÄÀÏ, ÀûÀÀÁõÀÇ È®´ë, Çõ½ÅÀûÀÎ Áøº¸´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿°ú °°Àº Ç¥Àû ¿ä¹ýÀÇ °³¹ßÀ» Æ÷ÇÔÇÑ ¾Ï ¿¬±¸¿Í Ä¡·áÀÇ Áøº¸·Î ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀÌ È®´ëµÇ¾ú½À´Ï´Ù. ÀÌ ¶§¹®¿¡ Ä¡·á ¿ä¹ýÀÇ ÀÏȯÀ¸·Î ½ºÇÁ¶óÀ̼¿ÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±×·¯³ª °­·ÂÇÑ °æÀï, ƯÇã ¸¸·á, ±ÔÁ¦ °úÁ¦, ºÎÀÛ¿ë, °¡°Ý ¹× »óȯÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀÇ ¼ºÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£ 2025³â-2032³â ½ÃÀå ±Ô¸ð ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR)À» Á¦°øÇÕ´Ï´Ù.
  • ¶Ç, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÇô, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ¼­ ÇØ¼³Çß½À´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã³ª ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ´ÙÀ½ ÆÄ¶ó¹ÌÅ͸¦ ¹ÙÅÁÀ¸·Î ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
  • º» º¸°í¼­·ÎºÎÅÍÀÇ ÅëÂûÀº ¸¶ÄÉÆÃ ´ã´çÀÚ³ª ±â¾÷ÀÇ °æ¿µÁøÀÌ, Àå·¡ÀÇ Á¦Ç° ¹ß¸Å, À¯Çü ¾÷, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÀÇ»ç °áÁ¤À» ½Ç½ÃÇÏ´Â °ÍÀ» °¡´ÉÇÏ°Ô ÇÒ °ÍÀÔ´Ï´Ù.
  • ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ °ü°èÀÚ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ´ë»ó ÀûÀÀÁõÀÇ º¸±Þ·ü, È¿´É ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ, ÀûÀÀÁõÀÇ È®´ë
    • °Ý·ÄÇÑ °æÀï, ƯÇãÀÇ ÇØÁö, ±ÔÁ¦»óÀÇ °úÁ¦
    • Çõ½ÅÀûÀÎ Áøº¸
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • PORTER ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À

Á¦4Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå, Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃøÀÇ ºÐ¼®
  • °æÁ¦¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå, ¿ëµµº°, 2020³â-2032³â

  • ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML)
  • Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ±Þ¼º ¸²ÇÁ¾Æ±¸¼º ¹éÇ÷º´(Ph ALL)

Á¦6Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå, ¿¬·ÉÃþº°, 2020³â-2032³â

  • ¼ºÀΠȯÀÚ
  • ¼Ò¾ÆÈ¯ÀÚ

Á¦7Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå, À¯Åë ä³Îº°, 2020³â-2032³â

  • º´¿ø ¹× Áø·á¼Ò
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • Àü¹® ¾à±¹

Á¦8Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå, Áö¿ªº°, 2020³â-2032³â

  • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
  • À¯·´
      • ¿µ±¹
      • µ¶ÀÏ
      • ÀÌÅ»¸®¾Æ
      • ÇÁ¶û½º
      • ½ºÆäÀÎ
      • ·¯½Ã¾Æ
      • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • Àεµ
      • ÀϺ»
      • ASEAN
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¸ß½ÃÄÚ
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
      • GCC
      • À̽º¶ó¿¤
      • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
      • ºÏ¾ÆÇÁ¸®Ä«
      • Áß¾Ó ¾ÆÇÁ¸®Ä«
      • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • Bristol-Myers Squibb(BMS)

Á¦10Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
SHW 25.06.17

Sprycel Market is estimated to be valued at USD 2.34 Bn in 2025 and is expected to reach USD 2.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 2.8% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 2.34 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 2.80% 2032 Value Projection: USD 2.84 Bn

Sprycel is the brand name for dasatinib, a medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Dasatinib works by inhibiting the activity of specific tyrosine kinases, which are enzymes involved in the growth and spread of cancer cells. Sprycel is a targeted medication primarily employed in the treatment of certain types of leukemia, specifically acute lymphoblastic leukemia (ALL), characterized by the presence of the Philadelphia chromosome (Ph+ ALL), and chronic myeloid leukemia (CML). Common side effects of Sprycel may include fatigue, headache, nausea, diarrhea, and fluid retention. Some patients may also experience more serious side effects, such as low blood cell counts, liver problems, and bleeding. Close monitoring by healthcare providers is important to manage and address any adverse effects. It is administered to both adults and children aged 12 months and older who are diagnosed with CML. Additionally, it is prescribed for adults and children in the same age group who are afflicted with a specific subtype of acute lymphoblastic leukemia known as Philadelphia chromosome-positive or Ph+ ALL. Leukemia is a malignancy involving immature white blood cells that develop within the bone marrow. In the normal course of events, as these white blood cells mature, they enter the bloodstream to combat infections and maintain the body's immune system.

Market Dynamics:

The increasing prevalence of targeted indications, their efficacy and safety profile, expanded indications, and innovative advancements are major factors expected to drive growth of the global sprycel market during the forecast period. Advancements in cancer research and treatment, including the development of targeted therapies like Sprycel, have expanded the options available to healthcare providers and patients. This has led to increased adoption of Sprycel as part of the treatment regimen.

However, strong competition, patent expiration, regulatory challenges, adverse effects, and pricing and reimbursement are expected to hamper the growth of the global Sprycel market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global Sprycel market, and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Sprycel market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb (BMS)
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Sprycel market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Sprycel market

Detailed Segmentation:

  • By Application:
    • Chronic myeloid leukemia (CML)
    • Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
  • By Age Group:
    • Adult Patients
    • Pediatric Patients
  • By Distribution Channel:
    • Hospitals and Clinics
    • Retail Pharmacies
    • Online Pharmacies
    • Specialty Pharmacies
  • By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • By Company Profiles:
    • Bristol-Myers Squibb (BMS)

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Global Sprycel, By Application
    • Market Global Sprycel, By Age Group
    • Market Global Sprycel, By Distribution Channel
    • Market Global Sprycel, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing prevalence of targeted indications, efficacy and safety profile, expanded indications
    • Strong competition, patent expiration, regulatory challenges
    • Innovative advancements
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Sprycel Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Sprycel Market, By Application, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Chronic myeloid leukemia (CML)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Sprycel Market, By Age Group, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adult Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pediatric Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Sprycel Market, By Distribution Channel, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals and Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Specialty Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Sprycel Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Bristol-Myers Squibb (BMS)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

10. Section

  • Research Methodology
  • About us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦